Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Designing a cancer therapeutic peptide by combining the mitochondrial targeting domain of Noxa and ErbB2-targeting moieties.

FEBS letters - 1 Jan 2018

Han Ji-Hye, Park Junghee, Seo Young-Woo, Kim Tae-Hyoung

Abstract excerpt

Many anticancer drugs target epidermal growth factor receptors to inhibit receptor tyrosine kinases and tumor growth. Here, we show that an ErbB2-targeting pronecrotic peptide (KWSY:MTD) selectively kills tumor cells expressing ErbB2 in vitro. An antibody against ErbB2 inhibits KWSY:MTD-induced cell death. KWSY:MTD causes membrane permeability which allows propidium iodide entry into the cytosol and the release...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Drug Design
Share to Jurkat Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MCF-7 Cells

Share to Mice, Inbred NOD

Share to Necrosis

Share to Proto-Oncogene Proteins c-bcl-2

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 29193033
DOI: 10.1002/1873-3468.12922

Genes

HMGB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Designing a cancer therapeutic peptide by combining the mitochondrial targeting domain of Noxa and ErbB2-targeting moieties.PMID 29193033Read ↗

Strategies to target the cancer driver MYC in tumor cellsSemantic proximity Read ↗

Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancerSemantic proximity Read ↗

Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.Semantic proximity Read ↗

Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancerSemantic proximity Read ↗

Liver-targeting chimeras as a potential modality for the treatment of liver diseasesSemantic proximity Read ↗

Patritumab deruxtecan induces immunogenic cell deathSemantic proximity Read ↗

Local Delivery of Accutox® Synergises With Immune-checkpoint Inhibitors at Disrupting Tumor GrowthSemantic proximity Read ↗

Rational Design for Nitroreductase (NTR)-Responsive Proteolysis Targeting Chimeras (PROTACs) Selectively Targeting Tumor TissuesSemantic proximity Read ↗

Targeting the mitochondria to enhance tumor suppression.Semantic proximity Read ↗

TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity.Semantic proximity Read ↗

Intracellular Delivery of Peptides and Proteins with an Engineered Membrane Translocation DomainSemantic proximity Read ↗

Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.